Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
Innate Pharma and Sobi have partnered to advance lacutamab in cutaneous T-cell lymphoma.
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
A New Era in Cutaneous T-cell Lymphoma Treatment
Jonathan Dickinson, CEO of Innate Pharma, faced a crucial challenge in advancing lacutamab toward a potential accelerated approval in Sézary syndrome, but the partnership with Sobi has enabled the initiation of the TELLOMAK-3 confirmatory Phase 3 study, a key step toward bringing this treatment to patients globally, as of August 10, 2026.
Innate Pharma SA and Swedish Orphan Biovitrum AB have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma. This partnership aims to advance lacutamab toward a potential accelerated approval in Sézary syndrome, a rare and aggressive leukemic form of cutaneous T-cell lymphoma.
Sobi will receive exclusive global rights to commercialize lacutamab upon potential accelerated approval. Innate will be eligible to receive up to $465 million related to the option for Sobi to get full development rights and to future regulatory and commercial milestones. This partnership marks a significant step forward in the development of lacutamab, a first-in-class anti-KIR3DL2 antibody.
"We are thrilled to partner with Sobi and enable TELLOMAK-3 initiation, the pivotal next step in advancing lacutamab toward a potential accelerated approval in Sézary syndrome," said Jonathan Dickinson, CEO of Innate Pharma. "Sobi is the ideal partner to help unlock the full potential of lacutamab. Their expertise in rare diseases, proven commercial capabilities, and global reach perfectly complement Innate’s expertise in CTCL clinical development. Together, we share the ambition to bring lacutamab to patients globally as quickly as possible."
The partnership between Innate Pharma and Sobi is expected to have a profound impact on the treatment of cutaneous T-cell lymphoma. With the initiation of the TELLOMAK-3 study, patients with Sézary syndrome may soon have access to a new and potentially life-changing treatment option. The study's results will be closely watched by the medical community, as they could pave the way for a new standard of care in the treatment of this rare and aggressive disease.
In addition to the potential benefits for patients, the partnership between Innate Pharma and Sobi also highlights the importance of collaboration in the development of new treatments. By working together, companies can pool their resources and expertise to bring new and innovative treatments to market more quickly. This partnership is a prime example of how collaboration can drive progress in the field of medicine and improve the lives of patients around the world.
Sources & Further Reading
How the Innate Pharma and Sobi Partnership Advances Cutaneous T-cell Lymphoma Treatment
The partnership between Innate Pharma and Sobi has the potential to significantly impact the treatment of cutaneous T-cell lymphoma, particularly in the rare and aggressive form of Sézary syndrome. With Sobi's expertise in rare diseases and commercial capabilities, lacutamab may become a viable treatment option for patients worldwide. The success of this partnership will depend on the results of the TELLOMAK-3 study, which will provide valuable insights into the safety and efficacy of lacutamab in patients with Sézary syndrome.
What Happens Next
- August 10, 2026 — The partnership between Innate Pharma and Sobi is announced, marking the initiation of the TELLOMAK-3 confirmatory Phase 3 study.
Comments